

## DAFTAR PUSTAKA

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. 2021;71(3):209–49.
2. 1. Jiang Y, Eveillard JR, Couturier MA, Soubise B, Chen JM, Gao S, et al. Asian population is more prone to develop high-risk myelodysplastic syndrome, concordantly with their propensity to exhibit high-risk cytogenetic aberrations. *Cancers (Basel)*. 2021;13(3):1–23.
3. Pangribowo S. Beban kanker di indonesia. Pusat Data Dan Informasi Kesehatan. Kementerian Kesehatan RI. Published online 2019:1–16.
4. Tarigan ADT, Ariawati K, Widnyana P. Prevalensi dan karakteristik anak dengan leukemia limfoblastik akut tahun 2011-2015 di RSUP Sanglah Denpasar. *Medicina*. 2019;50(2):391–5.
5. Namayandeh SM, Khazaei Z, Najafi ML, Goodarzi E, Moslem A. Global leukemia in children 0-14 statistics 2018, incidence and mortality and human development index (hdi): globocan sources and methods. *Asian Pacific J Cancer Prev*. 2020;21(5):1487–94.
6. Lezin ESt, Karafin MS., Bruhn R. Therapeutic impact of red blood cell transfusion on anemic outpatients: the retro study. *Trans* ; 59(6): 1934–1943
7. Fan BE, Christopher D, Gallardo CA, Sampath VS. Rationalising red blood cell transfusions in advanced haematological malignancies: a patient-centred approach. *Lancet Heal Longev*. 2022;3(1): e9–e10.
8. Ballo O, Fleckenstein P, Eladly F, Kreisel EM, Stratmann J, Seifried E, et al. Reducing the red blood cell transfusion threshold from 8·0 g/dl to 7·0 g/dl in acute myeloid leukaemia patients undergoing induction chemotherapy reduces transfusion rates without adversely affecting patient outcome. *Vox Sang*. 2020;115(7):570–8.
9. Chantepie SP, Mear JB, Parienti JJ, Bazin A, Benabed K, Cheze S, et al. Blood transfusion in hematologic intensive care unit. *Transfusion*. 2017;57(2):296–302.
10. J compilation 2020 BPL. *ISBT Sci Ser*. 2020;15 (introduction to blood transfusion: from donor to recipient): 255–330.

11. Farley A, Hendry C, McLafferty E. Blood components. *Nurs Stand.* 2012;27(13):35–42.
12. Molina-aguilar R, Jorge G. Pathophysiology of Alloimmunization. *Transfus Med Hemotherapy.* 2020:152–9.
13. Vidushi, Sidhu, M Shah NS. Evaluation of Incompatible Crossmatch. *Glob J Transfus Med AATM.* 2020;5(1):68–72.
14. Gerais M, Pereira G. Clinical and epidemiological profile of alloimmunized and autoimmunized multi-transfused patients against red blood cell antigens in a blood center of Hematology. *Hematol Transfus Cell Ther.* 2019;40(2):107–11.
15. A Victor Hoffbrand PAHM. *Kapita Selekta Hematologi.* 7 ed. Jakarta: EGC, 2016. 141-229
16. Davis AS, Viera AJ, Mead MD. Leukemia: An overview for primary care. *Am Fam Physician.* 2014;89(9):731–8.
17. Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, et al. *Williams hematology.* 9<sup>th</sup> edition. 9 ed. McGrawHill; 2016.
18. Tresckow J Von, Eichhorst B, Bahlo J, Hallek M. The treatment of chronic lymphatic leukemia. Published online 2019:41–6.
19. Ansell SM. Hodgkin lymphoma: a 2020 update on diagnosis, risk-stratification, and management. *Am J Hematol.* 2020;95(8):978–989.
20. Momotow J, Borchmann S, Eichenauer DA, Engert A, Sasse S. Hodgkin lymphoma—review on pathogenesis, diagnosis, current and future treatment approaches for adult patients. *J Clin Med.* 2021;10(5):1–17.
21. Singh R, Shaik S, Negi BS, Rajguru JP, Patil PB, Parihar AS, et al. Non-hodgkin's lymphoma: a review. *j fam med prim care.* 2020;9(4):1834–40.
22. Nasional K, Kanker P, (KPKN). Panduan nasional penanganan kanker limfoma non- hodgkin. Kementerian Kesehat REPUBLIK Indones. Published online 2015:5–6.
23. Woldu MA, Fentie AM, Tadesse TA. Treatment approaches of multiple myeloma. *IntechOpen.* Published online 2021:1–18.
24. Bird SA, Boyd K. Multiple myeloma: an overview of management. Published online 2019:1–13.

25. Garcia MG, Chien KS, Montalban-Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. *Am J Hematol.* 2020;95(11):1399–420.
26. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. *Blood.* 2012;120(12):2454–65
27. Wahidiyat PA, Adnani NB. Transfusi rasional pada anak. 2016;18(71):325–31.
28. Bhattacharya P, Samanta H, Nowroz AAN, Biswas R. An approach to inkompatibel cross-matched red cells: Our experience in a major regional blood transfusion center at Kolkata, Eastern India. *Asian J Transfus Sci.* 2018;12(1):51–56.
29. Legese B. Distribution of abo and rhesus blood group phenotypes among blood donors at bahir dar blood bank, Amhara, Northwest Ethiopia: A Retrospective Cross-Sectional Study. Published online 2021:849–54.
30. Irawaty I, AM R, Arif M. Characteristics of *crossmatch* types in compatibility testing on diagnosis and blood types using gel method. *Indones J Clin Pathol Med Lab.* 2018;23(1):36.
31. Swarup D, Dhot PS, Kotwal J, Verma AK. Comparative study of blood cross matching using conventional tube and gel method. *Med J Armed Forces India.* 2008;64(2):129–30
32. Hendrickson JE, Tormey CA, Haven W. Understanding red blood cell alloimmunization triggers. *Blood.* 2019:446–51.
33. Geraiis M, Pereira G. Clinical and epidemiological profile of alloimmunized and autoimmunized multi-transfused patients against red blood cell antigens in a blood center of Hematology. *Hematol Transfus Cell Ther.* 2019;40(2):107–11.
34. Purwati D, Rofinda ZD. Karakteristik pasien transfusi darah dengan inkompatibilitas *crossmatch* di utd rsup dr m djamil padang. *J Kesehat Andalas.* 2020;9(3):308–12.
35. Sehgal S, Puri V. *Crossmatch* Incompatibilities in blood bank - A Perplexing Scenario. *Online J Heal Allied Sci.* 2021;20(4):1–2.

36. Gerritsma. JJ, Omen. I, Meindert S, Schoot CE Van Der, Biemond BJ, Bom G Vander, et al. Blood reviews back to base pairs : what is the genetic risk for red bloodcell alloimmunization. Elsevier sci. 2021
37. Dyussenbayev A. Age periods of human life. ASSRJ. 2017;4(6):258–63
38. Molina-aguilar R, Jorge G. Pathophysiology of alloimmunization. Transfus Med Hemotherapy. 2020:152–9.
39. Desai PC, Deal AM, Pfaff ER, Qaqish B, Hebden LM, Park A, et al. Alloimmunization is associated with older age of transfused red blood cells in sickle cell disease, HHS Public Access. 2016;90(8):691–5.
40. Politou M, Valsami S, Dryllis G, Baka M, Stamoulis K, Christodoulaki M, et al. Retrospective study on prevalence, specificity, sex, and age distribution of alloimmunization in two general hospitals in athens. 2020;154–66.
41. Tangvarasittichai S. Impact of alloimmunization on transfusion-dependent patients. Ann Adv Chem. 2017; 1: 070-082.
42. Caamano J, Ulloa H. Frequency and specificity of red blood cell alloimmunization in chilean transfused patients. 2015;4–7.
43. Verduin EP, Brand A, Schonewille H. Is female sex a risk factor for red blood cell alloimmunization after transfusion? A Systematic Review. Transfus Med Rev [Internet]. 2012;26(4):342-353.e5. Available from:
44. Zalpuri S, Zwaginga JJ, le Cessie S, Elshuis J, Schonewille H, van der Bom JG. Red blood cell alloimmunization and number of red-blood-cell transfusions. Vox Sang 2012;144–9.
45. Abo RM, Fetouh E, Abd GM, Mahmoud R, Emam M, Kamel MM, et al. Transfusion and apheresis science frequency and specificity of red blood cell alloantibodies in multitransfused egyptian patients with hematological and nonhematological malignancies. Transfus Apher Sci [Internet]. 2020
46. Gehrie E. A., Tormey C. A. The influence of clinical and biological factors on transfusion-associated non- abo antigen alloimmunization: responders, hyper-responders, and non- responders. Transfusion medicine and hemotherapy Transfus Med Hemother. 2014,41 (6), 420-9.



47. Haslina N, Noor M, Arifin N, Hassan MN, Mustaffa R, Unit TM. Red cell alloimmunization among hemato-oncologic patients in a teaching hospital in Malaysia. 2019;28(1)
48. Rajeev TK, Jain A, Marwaha N, Prakash G, Sharma RR. Red cell alloimmunization in hematooncology patients transfused with packed red blood cells extended phenotype matched for Rh and Kell antigens versus the standard *crossmatched* units. ISBT Sci 2021, 16(4)
49. Dewi I, Dalimoenthe NZ, Tjandrawati A, Suraya N. Proportion of rhesus blood phenotypes at the blood donor unit in bandung city. IJCPML, 2019 March, 25 (2) :155 – 60
50. Ahuja T, Bhatnagar N, Shah M, Shah S, Patel T, Vora R. Evaluation of Incompatible *crossmatch* at a tertiary care blood center. IJSR; 2020
51. Martins P.R., Alves V.M., Pereira G.A., Moraes-Souza H. Frequência de anticorpos irregulares em politransfundidos no Hemocentro Regional de Uberaba-MG, de 1997 a 2005. Rev Bras Hematol Hemoter. 2008;30(4):272–6.
52. Neto OG, Alves VM, Pereira G, Souza HM, Martins PRJ. Clinical and epidemiological profile of alloimmunized and autoimmunized multi-transfused patients against red blood cell antigens in a blood center of minas gerais. Hematol Transfus Cell Ther. 2019;40(2):107–11.
53. Alves VM, Martins PRJ, Soares S, Araújo G, Schmidt LC, Costa SS de M, et al. Alloimmunization screening after transfusion of red blood cells in a prospective study. Rev Bras Hematol Hemoter [Internet]. 2012;34(Rév. Bras. Hematol. Hemoter., 2012 34(3))
54. Natukunda B, Schonewille H, Watering L, Brand A. Prevalence and specificities of red blood cell alloantibodies in transfused ugandans with different diseases. Vox Sanguinis, 2010: 167-71.
55. Evers, Zwaginga JJ, Tijmensen J, Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization, Dorothea, Vol. 102 No. 1. 2017
56. Fatmawati L, Laili NH, gambaran kasus inkompatibile mayor pada permintaan darah *packed red cell* di unit donor darah (udd) pmi kota surakarta pada bulan januari – maret tahun 2020, Avicenna : Journal of Health Research. 2020

57. Srihartaty, Uswiyanti O, Karakteristik pasien transfusi darah dengan hasil uji silang serasi inkompatibeldi utd pmi kabupaten bekasi, *Ensiklopedia Of Journal*. 2021
58. Pardosi BBH, Mulyantari NK, Wirawati IAP, Overview of transfusion reactions in patients with incompatible *crossmatch* at sanglah general hospital, denpasar, bali, indonesia, *Bali MedJ*. 2022
59. Ahrens N, Pruss A, Mayer B, Genth R, Kiesewetter H, Salama A. Association between alloantibody specificity and autoantibodies to red blood cells. *Transfusion*. 2008;48(1): 20–4.
60. Daniel AA, Orazi A, Robert PH, Borowitz MJ, Calvo KR, Kvasnicka HM, et al International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. *Blood* 2022; 140 (11): 1200–28
61. Conrath S, Vantilcke V, Parisot M, Maire F, Selles P, Ellenga N. Increased prevalence of alloimmunization in sickle cell disease? should we restore blood donation in french guiana. *Front. Med*. 2021
62. Ryder A, B, Zimring J, C, Hendrickson J, E: Factors Influencing RBC Alloimmunization: Lessons Learned from Murine Models. *Transfus Med Hemother* 2014 :406-19
63. Chou ST, Liem RI, Thompson AA, Challenges of alloimmunization in patients with haemoglobinopathies. *Br J Haematol*, 2012:394-404
64. Das SS, Biswar RN, Safi M, Zaman RU. Alloimmunization to erythrocyte antigens in patients receiving multiple blood transfusions: Clinico-immunohematological and demographic risk factors and impact of extended red cell phenotyping. *Glob J Transfus Med*. 2021, 6: 171-7
65. Pessoni LL, Ferreira MA, Silva JCRD, Alcantara KC. Red blood cell alloimmunization among hospitalized patients: transfusion reactions and low alloantibody identification rate. *Hematol Transfus Cell Ther*. 2018. 40: 326-31
66. K.E. Hudson, E. Lin, J.E. Hendrickson, A.E. Lukacher, J.C. Zimring. Regulation of primary alloantibody response through antecedent exposure to a microbial T-cell epitope. *Blood*, 2010: 3989-96

67. Solmaz S, Karacaoglu P, Gereklioglu C, Asma S, Korur A, Buyukurt N, et al. Red blood cell alloimmunization in patients with sickle cell disease in turkey: a single center retrospective cohort study. *Cukurova Med J*. 2016;41(4):622-627
68. Ugwu NI, Awodu OA, Bazuaye GN, Okoye AE. Red cell alloimmunization in multi-transfused patients with sickle cell anemia in Benin City, Nigeria. *Niger J ClinPract*. 2015;18:522-6.
69. Miller ST, Kim HY, Weiner DL, Wager CG, Gallagher D, Styles LA, et al. Red blood cell alloimmunization in sickle cell disease: prevalence in 2010. *Transfusion* 2013;53:704-9.
70. Haynes L, Agrawal A, Aging of the immune system: research challenges to enhance the health span of older adults, *Front. Aging*. 2020
71. Fink AL, Klein SL. The evolution of greater humoral immunity in females than males: implications for vaccine efficacy. *Curr Opin Physiol*. 2018
72. Czubak PK, Trelinski J, Stelmach P, Stelmach P, Madon A, Zbikowska HM, Increased oxidative stress in acute myeloid leukemia patients after red blood cell transfusion, but not platelet transfusion, results mainly from the oxidative/nitrative protein damage: an exploratory study. *J. Clin. Med*. 2021
73. Fasano RM, Booth GS, Miles M, Du L, Koyama T, Meier ER. et. al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. *Br J Haematol*, 2015; 168: 291-300
74. . Book BK, Volz MA, Ward EK, Eckert G.J, Pescovitz MD., Wiebke EA., Differences in Alloimmune Response Between Elderly and Young Mice, *Transplant. Proc.*2013: 45
75. Campbell-Lee SA, Ness PM. Packed Red Blood Cells and Related Products [Internet]. Second Edition. *Blood Banking and Transfusion Medicine: Basic Principles and Practice: Second Edition*. Elsevier Inc.; 2007. 250–8
76. Yadav A, Raturi G, Lokhande V, Aparna B. Prevalence of irregular red cell antibody in transfusion recipient vis-a-vis healthy blood donors attending a tertiary care hospital North India, 2017;12(2):105–11.
77. Obaid JM, Abo El-Nazar SY, Ghanem AM, El-Hadidi AS, Mersal BH. Red blood cells alloimmunization and autoimmunization among transfusion-

dependent beta-thalassemia patients in Alexandria province, Egypt. *Transfus Apher Sci.* 2015;53(1):52–7.

78. Langerbeins P, Eichhorst B. Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic. *Acta Haematol.* 2021;144(5):508-518.

79. Natukunda B, Schonewille H, Van de Watering L, Brand A. Prevalence and specificities of red blood cell alloantibodies in transfused Ugandans with different diseases. *Vox Sang.* 2010; 98(2): 167-71

